Qiming Venture Partners and Its Investors Win Multiple Awards on China FOF Research Center 2025 Annual Rankings
This is intended to encourage outstanding institutions and talent in private equity fund-of-funds and the broader fund industry, and to promote the healthy development of equity investment.
Recently, the China FOF Research Center officially released its 2025 annual rankings based on available data and research analysis, recognizing outstanding institutions and talent in the private equity fund-of-funds and fund industry, and promoting the healthy development of the equity investment sector. Qiming Venture Partners ranked No. 4 on the 2025 Best VC Funds list, No. 3 on the 2025 Best Fundraising Direct Investment Institutions list, and No. 6 on the 2025 Best Exit Direct Investment Institutions list. Duane Kuang, Founding Managing Partner of Qiming Venture Partners, was named to the 2025 Best VC Fund Investors TOP30.
Qiming Venture Partners received
2025 Best VC Fund — No. 4
2025 Best Fundraising Direct Investment Institution — No. 3
2025 Best Exit Direct Investment Institution — No. 6
Duane Kuang, Founding Managing Partner of Qiming Venture Partners
received
2025 Best VC Fund Investor — TOP30
The China FOF Research Center noted that 2025 is a year of continued deepening adjustment for the equity investment industry, with both opportunities and challenges coexisting. Currently, the industry is strengthening its focus on early-stage, small-scale, long-term, and hard-tech investments, cultivating technological innovation in more enterprises with patient capital. Under the new circumstances, the equity investment industry is opening a new landscape.
Source | China FOF Research Center
Past Coverage
Qiming Perspectives | Duane Kuang, Qiming Venture Partners: Hong Kong Has Become an Important International Financing Channel for Hard-Tech Enterprises Qiming Honors | 5 Qiming Venture Partners Investors Named to ChinaVenture 2025 Annual Investors Ranking Qiming Honors | 5 Qiming Venture Partners Investors Named to Forbes China 2025 Midas List
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative enterprises, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many of Qiming Venture Partners' portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ: HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ: WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), GenScript ProBio (688520.SH), Insilico Medicine (03696.HK), Hepb Therapeutics, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, and others.